Volatile Organic Compounds (VOCs) in exhaled breath as biomarkers for lungcancer diagnosis. A screening-based study in high-risk subjects

12 settembre 2023

Catino A.’, d’Alonzo G.’), de Gennaro G. 2), De Summa S.”), Di Gilio A. 2), Galetta D., Nisi M. 2). Palmisani J. 2), Varesano N. “”,
“Thoracic Oncology Unit-Clinical Cancer Centre “Giovanni Paolo II”-Viale Orazio Flacco 65.70124-BARI © Department of Bioscience, Biotechnologies and Environment – University of Bari, 70126 Bari,Italy

Introduction.

Low Dose Computed Tomography (LDCT) screening for Lung Cancer (LC) early diagnosis in high-risk subjects is growing evidence and application although it results in the frequent detection of small pulmonary nodules. Therefore, to distinguish between malignant and benign nodules and to diagnose LC further examinations and invasive diagnostic procedure are needed increasing anxiety in patients.
Recently, VOCs determination in exhaled breath has been growing interest as possible biomarker of some neoplasms as LC; hence also considering its non-invasive and cost-effective feature, breath analysis could represent a promising tool for early LC diagnosis and nodules management. The aim of this study is to explore the role of breath analysis in this suberoup of high-risk subiects in association with LDCT screening, by evaluating the VOCs pattern as a biological biomarker potentially able to improve the early diagnosis of IC

Articoli correlati

My Agile Privacy
Questo sito utilizza cookie tecnici e di profilazione. Cliccando su accetta si autorizzano tutti i cookie di profilazione. Cliccando su rifiuta o la X si rifiutano tutti i cookie di profilazione. Cliccando su personalizza è possibile selezionare quali cookie di profilazione attivare.
Attenzione: alcune funzionalità di questa pagina potrebbero essere bloccate a seguito delle tue scelte privacy